ALSO NOTED: Aptuit to acquire EaglePicher; Immunicon touts Phase III data; and much more...

> Aptuit announced today that it has signed a deal to acquire EaglePicher Pharmaceutical Services--the first step in Aptuit's plan to build capabilities in active pharmaceutical ingredient development and drug substance manufacturing. Release

> Immunicon is touting the results of a Phase III trial enumerating circulating tumor cells in patients with metastatic colorectal cancer. The primary endpoint was that the number of circulating tumor cells 3-5 weeks after the initiation of therapy would agree with a patient's response to therapy as determined by imaging 6-12 weeks after initiation of therapy. Immunicon is developing new research tools. Release

> UCB reports it has received positive data on two epilepsy drugs but faces a delay in a Phase III trial of a new therapy for lupus. Report

> Allergan is preparing to begin distribution of Juvederm, its new wrinkle therapy. Report

> Genentech has added a new warning on Avastin that calls attention to a link to a rare brain disorder. Report

> Sanofi-Aventis says it will co-promote the antihistamine Xyzal with UCB in the U.S. Report

> Quigley Pharma says it will proceed to a Phase IIb study of QR-333 after an earlier study demonstrated it could be safely administered to patients with diabetic peripheral neuropathy. Release

> Chutes & Ladders: Zestra Laboratories has named Younis Zubchevich as chief executive officer. Release

And Finally… A government advisory panel said that affordable health coverage for all should be established policy. The panel, however, didn't say how they thought that could be achieved. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.